Anthrax: all 65 studies
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
- Cigarette Filter StudyRecruitingNCT07348679Not applicable
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not yet recruitingNCT07268612
- Combined Gastrointestinal Decontamination in Acute Severe PoisoningRecruitingNCT07201311Phase 2
- SGLT2 Inhibitor Utilization Re-perfusion TherapyNot yet recruitingNCT06858436Phase 4
- A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe AnthraxRecruitingNCT06365073
- Activated CHARcoal in Poisoned Patient - Pilot TrialRecruitingNCT05471479Phase 4
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
- An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. AnthracisNot yet recruitingNCT03088111Phase 4
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
- Anthrax AV7909 Liquid vs LyophilizedCompletedNCT04660201Phase 1Results posted
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCompletedNCT04067011Phase 2Results posted
- VELOCITY: An Anthrax Vaccine Clinical StudyCompletedNCT03877926Phase 3Results posted
- BARDA Securing Anthrax Immunity For the ElderlyCompletedNCT03518125Phase 2Results posted
- Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCompletedNCT02339155Phase 4Results posted
- An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With ReinjectionCompletedNCT02016963Phase 2/3Results posted
- Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult VolunteersCompletedNCT01952444Phase 1Results posted
- Intramuscular Dose-Escalation Study With ETI-204 in Adult VolunteersCompletedNCT01932437Phase 1Results posted
- Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult VolunteersCompletedNCT01932242Phase 1Results posted
- Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult VolunteersCompletedNCT01929226Phase 1Results posted
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedNCT01770743Phase 2Results posted
- Ciprofloxacin BioThrax Co-Administration StudyCompletedNCT01753115Phase 2Results posted
- Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA ScheduleCompletedNCT01641991Phase 4Results posted
- Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01491607Phase 3Results posted
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedNCT01263691Phase 1Results posted
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)CompletedNCT00845650Phase 1/2Results posted
- Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route ChangeCompletedNCT00119067Phase 4Results posted
- Comparative Clinical Assessment of Charcoal and Conventional ToothbrushesCompletedNCT07563413Not applicable
- Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol AssayActive, not recruitingNCT07220031
- The Effect of AC-134 in Chronic Kidney DiseasesCompletedNCT06441435Not applicable
- Anthrax AV7909 Boost Evaluation StudyCompletedNCT05997264Phase 2
- Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic SystemTerminatedNCT05672875
- NasoShield in Healthy Adults to Study Safety and ImmunogenicityCompletedNCT04415749Phase 1
- Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)CompletedNCT04320485
- A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy AdultsCompletedNCT04148118Phase 1
- Febrile Whole Blood Specimen Collection and TestingCompletedNCT03498027
- NasoShield Study of Safety and ImmunogenicityCompletedNCT03352466Phase 1
- Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral AnticoagulantsWithdrawnNCT02969746Phase 4
- A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult SubjectsCompletedNCT02655549Phase 1
- Special Drug Use Investigation of Ciproxan Injection in PediatricsCompletedNCT02555059
- PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax VaccineCompletedNCT02239172Phase 1
- A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCompletedNCT01979406Phase 1
- Efficacy and Safety of Anthrax Vaccine, GC1109CompletedNCT01867957Phase 1
- Glyburide Advantage in Malignant Edema and Stroke - Remedy PharmaceuticalsCompletedNCT01794182Phase 2
- BioThrax® (Anthrax) Vaccine in Pregnancy RegistryCompletedNCT01653392
- A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109CompletedNCT01624532Phase 2
- Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult VolunteersCompletedNCT01453907Phase 1
- Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal SubjectsCompletedNCT01265745Phase 1
- Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)CompletedNCT01202695Phase 1
- Ph1 Study of Valortim and Doxycycline in HumansTerminatedNCT00964834Phase 1
- Ph1 Study of Valortim and Ciprofloxacin in HumansSuspendedNCT00964561Phase 1
- Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCompletedNCT00448253Phase 1
- Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine AdsorbedCompletedNCT00170469Phase 2
- Phase II Study of Range and Schedule of rPA DosesCompletedNCT00170456Phase 2
- Monoclonal Antibody for Treatment of Inhalation AnthraxCompletedNCT00138411Phase 1
- UMD rPA Regimen Trial in AdultsTerminatedNCT00133484Phase 2
- VHA Clinicians and Bioterror Events: Interactive Web-based LearningCompletedNCT00123396Not applicable
- Anthrax Vaccine Clinical TrialsCompletedNCT00114621Phase 1
- Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen VaccineCompletedNCT00103467Phase 1
- Trial of rPA-102 Vaccine in Healthy Adult VolunteersCompletedNCT00100724Phase 2
- Anthrax-rPA: Safety, Tolerability, ImmunogenicityCompletedNCT00063843Phase 1
- A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy AdultsCompletedNCT00057525Phase 1
- Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated RecipientsCompletedNCT00050310
- Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune GlobulinCompletedNCT00031291